OXB enters licensing agreement with Viral Vector Manufacturing Facility

OXB entered into a licensing and option agreement with Viral Vector Manufacturing Facility. Further to the non-binding terms sheet signed in October 2025, this agreement provides VVMF with a worldwide, non-exclusive licence to OXB’s proprietary inAAVate platform know-how and intellectual property, with an option to extend the licence to its proprietary LentiVector platform. In return, OXB will receive a low single-digit million licence fee and is eligible for future payments related to the use of its platforms. This five-year licence underpins the strategic collaboration between OXB and VVMF, enabling VVMF to accelerate its operational and commercial readiness to provide advanced viral vector technologies to customers, capturing global demand with a particular focus on the fast-growing APAC region, and positioning Australia as a regional hub for high-quality cell and gene therapy manufacturing.